4//SEC Filing
Rhode Peter 4
Accession 0001209191-22-003785
CIK 0001828673other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 5:42 PM ET
Size
11.5 KB
Accession
0001209191-22-003785
Insider Transaction Report
Form 4
Rhode Peter
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-01-14$0.21/sh+1,714$360→ 48,499 total - Exercise/Conversion
Stock Option Grant (Right to Buy)
2022-01-14−1,714→ 6,857 totalExercise: $0.21Exp: 2030-12-22→ Common Stock (1,714 underlying) - Exercise/Conversion
Common Stock
2022-01-14$0.14/sh+1$0→ 48,500 total - Exercise/Conversion
Stock Option Grant (Right to Buy)
2022-01-14−1→ 51,427 totalExercise: $0.14Exp: 2029-12-19→ Common Stock (1 underlying)
Footnotes (2)
- [F1]20% of the total shares subject to the stock option grant vested on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024, subject to the reporting person's continuous service through the applicable vesting date.
- [F2]These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.
Documents
Issuer
HCW Biologics Inc.
CIK 0001828673
Entity typeother
Related Parties
1- filerCIK 0001866276
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 5:42 PM ET
- Size
- 11.5 KB